Scienture Holdings, Inc., through its wholly owned subsidiary, Scienture, LLC, is a specialty pharmaceutical company focused on providing enhanced value to patients, physicians and caregivers by offering specialty products to satisfy unmet market needs. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The Company's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
09/26/09	$3.760	-2.59%	32,858
08/26/08	$3.860	-6.54%	70,947
07/26/07	$4.130	+9.84%	1,08,710
06/26/06	$3.760	+1.35%	2,18,016
05/26/05	$3.710	-6.55%	2,49,918

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.760USD

Average target price

37.50USD

Spread / Average Target

+897.34%

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - Scienture Holdings, Inc.

Revisions to estimates

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Scienture Holdings, Inc.

Company calendar

Market Closed - Nasdaq 01:30:00 10/10/2026 am IST			5-day change	1st Jan Change
3.760 ^USD	-2.59%		-5.29%	-70.51%

14/08	Scienture Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
12/08	Scienture Holdings Announces Commercial Launch and Fulfillment of Initial Purchase Orders of Rezenopy Nasal Spray 10 Mg	CI

Market Cap	61.76L 55.16L 51.31L 46.67L 88.12L 60Cr 88.5L 6.18Cr 2.42Cr 30Cr 2.32Cr 2.27Cr 98Cr	P/E 2026 *	-0.65x	P/E 2027 *	-
Enterprise Value	61.76L 55.16L 51.31L 46.67L 88.12L 60Cr 88.5L 6.18Cr 2.42Cr 30Cr 2.32Cr 2.27Cr 98Cr	EV / Sales 2026 *	1.29x	EV / Sales 2027 *	0.36x
Free-Float	77.92%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq	SCNX	Delayed
Tradegate	4E40	Real-time
CBOE	SCNX	Real-time
Deutsche Boerse AG	4E40	Delayed

14/08	Scienture Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
12/08	Scienture Holdings Announces Commercial Launch and Fulfillment of Initial Purchase Orders of Rezenopy Nasal Spray 10 Mg	CI
09/07	Scienture Holdings, Inc. Completes Manufacturing of Commercial Launch Inventory and Begins Shipments of Rezenopy Nasal Spray 10 Mg to U.S. Pharmaceutical Wholesalers	CI
19/06	Scienture Holdings Expands Arbli Payor Coverage and Commercial Access	CI
09/06	Scienture Holdings, Inc. Secures Formulary Coverage for REZENOPYTM with Large National Health Plan and Expands Commercial Team	CI
02/06	Scienture Secures US Patent Protection for Rezenopy Through 2041	MT
30/05	Scienture - Eric Sherb resigns as CFO effective May 26, 2026	RE
30/05	Scienture Holdings, Inc. Announces CFO Changes, Effective May 26, 2026	CI
16/05	Scienture Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
07/05	Scienture secures $11.0 million in non-dilutive debt financing to accelerate growth of approved product portfolio and advancement of research and development pipeline	RE
07/05	Scienture Holdings, Inc. Secures $11 Million in Non-Dilutive Debt Financing	CI
27/04	Scienture Holdings, Inc. announced that it has received $11 million in funding	CI
30/03	Scienture reports year end 2025 financial results and provides business update	RE

Scienture Holdings, Inc. Share Price

Stocks

SCNX

US80880X2036

Pharmaceuticals

Valuation: Scienture Holdings, Inc.

Chart: Scienture Holdings, Inc.

Latest news: Scienture Holdings, Inc.

Last Transcript: Scienture Holdings, Inc.

Analysts' recommendations: Scienture Holdings, Inc.

Press Releases: Scienture Holdings, Inc.

Quotes and Performance

Price Extremes

Latest insider transactions

Pharmaceuticals Wholesale

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

14/25/14	Top Midday Decliners	MT
01/23/01	EF Hutton Assumes Trxade Health at Buy With $1.25 Price Target	MT
28/23/28	Maxim Adjusts Price Target on Trxade Health to $1.75 From $2.50, Maintains Buy Rating	MT
10/22/10	Maxim Adjusts Price Target for TRxADE Health to $4 From $7, Maintains Buy Rating	MT
29/22/29	Maxim Adjusts TRxADE HEALTH's Price Target to $7 from $11, Maintains Buy Rating	MT

05/10	SCIENTURE Announces Arbli Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals	AQ
02/10	SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals	AQ
01/10	Scienture Holdings, Inc. Announces Reverse Stock Split	AQ
22/09	SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner	AQ
09/09	SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026	AQ

1 day	-2.59%
1 week	-5.29%
Current month	-42.11%
1 month	-56.77%
3 months	-59.36%
6 months	-54.83%
Current year	-70.51%

1 week	3.23	4.26
1 month	3.23	8.82
Current year	3.23	16.11
1 year	3.23	65
3 years	3.23	335.5
5 years	3.23	335.5
10 years	3.23	335.5

Date	Insider	Type	Main position	Quantity	% Market Cap.
19/09/24	Narasimhan Mani	Conversion	Director	29,27,538	-
19/09/24	Shankar Hariharan	Conversion	Chief Executive Officer	38,53,296	-
25/07/24	Narasimhan Mani	Other	Director	57,977	4.1225%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SCIENTURE HOLDINGS, INC.	-2.59%	-5.29%	-78.55%	-	61.76L
ELI LILLY AND COMPANY	+0.83%	+3.19%	+41.49%	+94.83%	1,05100Cr
JOHNSON & JOHNSON	+1.93%	+2.11%	+37.08%	+67.40%	63TCr
ABBVIE INC.	+1.49%	+5.19%	+19.94%	+85.13%	49TCr
MERCK & CO., INC.	+2.26%	+0.90%	+69.32%	+40.73%	36TCr
ROCHE HOLDING AG	+1.45%	+3.50%	+23.29%	+40.84%	34TCr
NOVARTIS AG	+1.17%	+2.37%	+13.47%	+32.81%	27TCr
ASTRAZENECA PLC	+0.89%	+1.08%	-6.13%	+9.63%	25TCr
AMGEN INC.	+1.82%	+2.94%	+42.99%	+46.29%	22TCr
GILEAD SCIENCES, INC.	+2.77%	+4.44%	+29.01%	+96.43%	19TCr
Average	+1.20%	+1.75%	+19.19%	+57.12%	38.04TCr
Weighted average by Cap.	+1.47%	+2.44%	+33.36%	+66.30%

	2026 *	2027 *
Net sales	47.89L 42.77L 39.79L 36.19L 68.33L 46Cr 68.63L 4.79Cr 1.88Cr 24Cr 1.8Cr 1.76Cr 76Cr	1.72Cr 1.54Cr 1.43Cr 1.3Cr 2.46Cr 166.63Cr 2.47Cr 17Cr 6.75Cr 85Cr 6.47Cr 6.32Cr 272.62Cr
Net income	-96.22L -85.93L -79.94L -72.71L -1.37Cr -93Cr -1.38Cr -9.62Cr -3.77Cr -47Cr -3.61Cr -3.53Cr -152.36Cr	1L 1L 1L 1L 2L 1.31Cr 2L 13.5L 5L 66.61L 5L 5L 2.14Cr
Net Debt	-	-